AXSM vs TEM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of just 3/9, indicating significant operational and profitability concerns. Despite strong revenue growth of 63.2% and a bullish analyst recommendation, the company is deeply unprofitable with a -40.89% profit margin, negative ROE of -275.50%, and a high debt/equity ratio of 2.96. Valuation metrics are stretched, with a forward P/E of 423x and a price-to-book of 126.85, while insider selling of $85.54M in the last six months signals strong bearish sentiment from management. Although the stock has delivered impressive price performance over the past year (+79%), these gains appear disconnected from fundamentals, increasing vulnerability to downside correction.
Tempus AI exhibits critical financial fragility, highlighted by a Piotroski F-Score of 1/9, indicating severe weakness across profitability and operational efficiency. While the company demonstrates explosive revenue growth of 83% YoY, this is offset by deep negative margins and a high Debt/Equity ratio of 2.70. The bearish outlook is further reinforced by aggressive insider selling, including significant divestments by the CEO and CFO, and a technical trend score of 0/100. Despite analyst optimism, the fundamental health metrics suggest a high-risk profile.
Compare Another Pair
Related Comparisons
AXSM vs TEM: Head-to-Head Comparison
This page compares Axsome Therapeutics, Inc. (AXSM) and Tempus AI, Inc. (TEM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.